Patent Claims

1. Tumour vaccine based on tumour antigens, characterised in that it contains, as active constituent, in addition to a tumour antigen source, a release system with delayed release of the active substance for IFN-γ, the effective dose of IFN-γ being 50 ng to 5 μg and the release interval being from half an hour to 8 days.
2. Tumour vaccine according to claim 1, characterised in that the effective dose of IFN-γ is 100 ng to 2 μg.
3. Tumour vaccine according to claim 2, characterised in that the effective dose of IFN-γ is 100 ng to 1 μg.
4. Tumour vaccine according to one of claims 1 to 3, characterised in that the release interval is from half an hour to 2 to 3 days.
5. Tumour vaccine according to claim 4, characterised in that about 75% of the dose of IFN-γ is released within an interval of between one hour and 3 days.
6. Tumour vaccine according to one of claims 1 to 5, characterised in that the release system with delayed release of the active substance consists of liposomes.
7. Tumour vaccine according to claim 6, characterised in that the liposomes contain >90 % of the IFN-γ enclosed therein and <10 % adsorbed on the outside.
8. Tumour vaccine according to one of claims 1 to 5, characterised in that the release system with delayed release of the active substance consists of microspheres.
9. Tumour vaccine according to one of claims 1 to 5, characterised in that the release system with

delayed release of the active substance consists of minipellets.

10. Tumour vaccine according to one of claims 1 to 9, characterised in that the tumour antigen source consists of tumour cells.

11. Tumour vaccine according to claim 10, characterised in that the tumour cells are allogenic tumour cells.

12. Tumour vaccine according to claim 10 oder 11, characterised in that the tumour cells are charged with peptides derived from tumour antigens.

13. Tumour vaccine according to one of claims 1 to 9, characterised in that the tumour antigen source consists of antigen-presenting cells which are charged with tumour antigen peptides.

14. Tumour vaccine according to one of claims 1 to 9, characterised in that the tumour antigen source consists of tumour antigens as such or peptides derived therefrom.

add A21

Add

CS